JMP Securities lowered the firm’s price target on OptimizeRx (OPRX) to $8 from $16 and keeps an Outperform rating on the shares. OptimizeRx reported a disappointing Q3 miss and guide-down, but JMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback